Sponsor or institution
Clinical trials and research at ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
As of November 12, 2026, Find a Trial lists 6 clinical trials run by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. that are recruiting, in China. By phase: Phase 1/2 (2), Phase 1 (2), Early Phase 1 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| IMC-003 in PAH patients on background therapy | Phase 1/2 | Beijing, Beijing Municipality and 28 other locations | Recruiting | May 18, 2026 |
| Randomized double-blind placebo-controlled dose-escalation of IMC-003 injections in healthy postmenopausal women | Phase 1 | Chengdu, Sichuan | Recruiting | Aug 12, 2025 |
| IMC-001 injection to improve plaque stability in people with acute coronary syndrome | Early Phase 1 | Nanyang, Henan and 1 other locations | Recruiting | Jan 23, 2025 |
| Combination therapy for advanced solid tumors | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Jan 8, 2025 |
| Evaluating IMM01 with Azacitidine for Newly Diagnosed Chronic Myelomonocytic Leukemia | Phase 3 | Hefei, Anhui and 42 other locations | Recruiting | Oct 18, 2024 |
| IMC-002 and IMM0306S for active systemic lupus erythematosus | Phase 1/2 | Beijing | Recruiting | Aug 2, 2024 |
All recruiting trials (6)
-
IMC-003 in PAH patients on background therapy
This study tests whether IMC-003 added to patients’ current PAH treatment can help people with pulmonary arterial hypertension who still have symptoms.
-
Randomized double-blind placebo-controlled dose-escalation of IMC-003 injections in healthy postmenopausal women
This will test single and multiple injections of IMC-003 to see if they are safe and how the body handles them in healthy postmenopausal women.
-
IMC-001 injection to improve plaque stability in people with acute coronary syndrome
This trial will test whether injections of IMC-001, added to standard medical therapy, can improve atherosclerotic plaque stability in adults with acute coronary syndrome.
-
Combination therapy for advanced solid tumors
This study is testing a new combination treatment for people with advanced solid tumors, including triple-negative breast cancer and liver cancer, to see if it works better after other treatments have not helped.
-
Evaluating IMM01 with Azacitidine for Newly Diagnosed Chronic Myelomonocytic Leukemia
This study is testing if a new treatment combining IMM01 with azacitidine can help people who have just been diagnosed with chronic myelomonocytic leukemia feel better and live longer compared to those getting a placebo with azacitidine.
-
IMC-002 and IMM0306S for active systemic lupus erythematosus
This study tests IMC-002 and IMM0306S to see if they help adults with active lupus while they continue their usual medications.
Quick answers
How many clinical trials run by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 1: 2, Early Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.